Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Argenica Therapeutics Ltd

AGN.AX ✗ NOT COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.12

▲ +0.00%

Market Cap $15.40M · Vol 67.01K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$15.40M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

56.25

Momentum

Beta

1.23

vs Market

52W High

$0.55

75.92% below

52W Low

$0.06

100.30% above

Volume

67.01K

Avg 233.03K

P/B

13.49

Price-to-book

ROE

N/A

Return on equity

Free Float

68.64%

Public shares

Shariah Compliance8 STANDARDS

✗ Argenica Therapeutics Ltd (AGN.AX) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AGN.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-2.86%

+17.24%

+13.33%

-34.62%

YTD

-42.37%

-75.00%

-53.95%

-26.09%

Financials & Valuation

TTM · Annual

Total Revenue	$337.39K
Net Income	$-4,718,080.00
Revenue Growth (YoY)	-65.84%
Gross Margin	100.00%
Operating Margin	-1,991.10%
Net Profit Margin	-1,398.41%
ROE	N/A
ROA · ROIC	-52.31% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	189.02
P/B	13.49
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	128.46M

Technical Indicators

50-Day SMA	$0.09
200-Day SMA	$0.14
RSI (14)	56.25
Beta	1.23
52-Week High	$0.55
52-Week Low	$0.06

Volume Today	67.01K
Avg Daily Volume (30D)	233.03K
Relative Volume	0.29x
Volatility (10D)	83.73
Volatility (30D)	105.29
Free Float	68.64%

Analyst Consensus

N/A

Current Price $0.12

Mean Target N/A

52W Low$0.06 52W High$0.55

Current

Target

$0.06 $0.55

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG010YS0TL2

ISINAU0000150328

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Argenica Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company develops neuroprotective therapeutics for patients following stroke and other acute neurological injuries. Its drug candidate, ARG-007, is designed to protect vulnerable brain tissue by reducing cell death and limiting secondary damage after an ischemic event. The Company has completed a Phase I clinical trial in healthy human volunteers to assess the safety and tolerability of a single dose of ARG-007. It has completed a Phase II clinical trial in ischaemic stroke patients, as well as continuing to generate preclinical data in other neurological conditions. The ARG-007 has a plurifunctional mechanism of action, affecting neuronal excitotoxicity, calcium influx and mitochondrial dysfunction, and reducing the activation of damaging proteolytic enzymes which enhances its neuroprotective potential and translational clinical effectiveness.